{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(5)"],"submitter":["Lee C"],"pubmed_abstract":["<h4>Background</h4>The use of immune checkpoint inhibitors (ICI) is associated with cardiovascular (CV) events, and patients with pre-existing autoimmune disease are at increased CV risk.<h4>Objectives</h4>The aim of this study was to characterize the risk for CV events in patients with pre-existing autoimmune disease post-ICI.<h4>Methods</h4>This was a retrospective study of 6,683 patients treated with ICIs within an academic network. Autoimmune disease prior to ICI was confirmed by chart review. Baseline characteristics and risk for CV and non-CV immune-related adverse events were compared with a matched control group (1:1 ratio) of ICI patients without autoimmune disease. Matching was based on age, sex, history of coronary artery disease, history of heart failure, and diabetes mellitus."],"journal":["JACC. CardioOncology"],"pagination":["660-669"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9830202"],"repository":["biostudies-literature"],"pubmed_title":["Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy."],"pmcid":["PMC9830202"],"pubmed_authors":["Taron J","Hoffmann U","Reynolds KL","Mayrhofer T","Schoenfeld S","Gongora CA","Zhang L","Faje A","Drobni ZD","Rambarat PK","Lee C","Alvi RM","Zafar A","Gilman HK","Murphy SP","Hartmann SE","Mosarla RC","Zlotoff DA","Sullivan RJ","Raghu VK","Neilan TG"],"additional_accession":[]},"is_claimable":false,"name":"Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy.","description":"<h4>Background</h4>The use of immune checkpoint inhibitors (ICI) is associated with cardiovascular (CV) events, and patients with pre-existing autoimmune disease are at increased CV risk.<h4>Objectives</h4>The aim of this study was to characterize the risk for CV events in patients with pre-existing autoimmune disease post-ICI.<h4>Methods</h4>This was a retrospective study of 6,683 patients treated with ICIs within an academic network. Autoimmune disease prior to ICI was confirmed by chart review. Baseline characteristics and risk for CV and non-CV immune-related adverse events were compared with a matched control group (1:1 ratio) of ICI patients without autoimmune disease. Matching was based on age, sex, history of coronary artery disease, history of heart failure, and diabetes mellitus.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-04T07:21:04.524Z","creation":"2025-04-04T07:21:04.524Z"},"accession":"S-EPMC9830202","cross_references":{"pubmed":["36636443"],"doi":["10.1016/j.jaccao.2022.11.008"]}}